Literature DB >> 31297632

Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017.

Fei Li1, Qing Li1, Yubo Liu1, Jing Han1, Wei Zheng1, Yini Huang1, Xueyi Zheng1, Longhui Cao2, Jian-Hua Zhou3.   

Abstract

PURPOSE: To assess the diagnostic performance of the LR-M criteria of Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System version 2017 in differentiating intrahepatic cholangiocarcinoma (ICC) from hepatocellular carcinoma (HCC) in patients with and without risk factors for HCC.
METHODS: Fifty-four ICC in patients with risks and 55 ICC in patients without risks and matched control cases of HCC with and without risks (n = 59 and n = 55, respectively) were enrolled. The enhanced features of the lesions were retrospectively analyzed according to LR-M criteria. The diagnostic performances including the area under the receiver operating characteristic curve (AUC), sensitivity, and specificity of LR-M criteria were assessed. RESULT: Peripheral rim-like hyperenhancement, early washout (< 45 or 60s), and marked washout did not differ between ICCs with and without risks, while all of these features were more common in ICCs than in HCCs (p < 0.05) no matter if patients were with and without risk factors. Using the LR-M criteria to differentiate ICC from HCC, the AUC, sensitivity, specificity, and accuracy were 0.92, 97.25%, 87.72%, and 92.38%, respectively. If early washout onset was adjusted to < 45 s, the specificity was significantly increased to 95.61% (p = 0.004) without losing sensitivity (96.33%, p = 0.945). The rate of HCCs misdiagnosed as ICCs would decrease from 12.3 to 4.4%.
CONCLUSION: Although the LR-M criteria showed high sensitivity in distinguishing ICCs from HCCs in patients with and without risks, the specificity would be significantly increased after adjustments to current criteria. KEY POINTS: • The LR-M criteria of CEUS-LI-RADS v2017 could be used for distinguishing ICC from HCC not only in patients with risk factors for HCC but also in those without risk factors. • The diagnostic performance of differentiating ICC from HCC by using the LR-M criteria showed high AUC (0.92), high sensitivity (97.25%), intermediate specificity (87.72%), and high accuracy (92.38%). • If the onset of early washout was adjusted to < 45 s, the specificity was significantly increased from 87.72 to 95.61% (p = 0.004) without losing sensitivity (p = 0.945), and the rate of HCCs misdiagnosed as ICCs would decrease from 12.3 to 4.4%.

Entities:  

Keywords:  Contrast media; Hepatocellular carcinoma; Intrahepatic cholangiocarcinoma; Ultrasonography

Mesh:

Substances:

Year:  2019        PMID: 31297632     DOI: 10.1007/s00330-019-06317-2

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  29 in total

1.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

Authors: 
Journal:  Eur J Cancer       Date:  2012-03       Impact factor: 9.162

2.  Dynamic enhancement pattern of intrahepatic cholangiocarcinoma on contrast-enhanced ultrasound: the correlation with cirrhosis and tumor size.

Authors:  Qing Lu; Li-Yun Xue; Wen-Ping Wang; Bei-Jian Huang; Cui-Xian Li
Journal:  Abdom Imaging       Date:  2015-08

3.  Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver--update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS.

Authors:  M Claudon; C F Dietrich; B I Choi; D O Cosgrove; M Kudo; C P Nolsøe; F Piscaglia; S R Wilson; R G Barr; M C Chammas; N G Chaubal; M-H Chen; D A Clevert; J M Correas; H Ding; F Forsberg; J B Fowlkes; R N Gibson; B B Goldberg; N Lassau; E L S Leen; R F Mattrey; F Moriyasu; L Solbiati; H-P Weskott; H-X Xu
Journal:  Ultraschall Med       Date:  2012-11-05       Impact factor: 6.548

4.  Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma.

Authors:  John Bridgewater; Peter R Galle; Shahid A Khan; Josep M Llovet; Joong-Won Park; Tushar Patel; Timothy M Pawlik; Gregory J Gores
Journal:  J Hepatol       Date:  2014-03-27       Impact factor: 25.083

5.  The Degree of Contrast Washout on Contrast-Enhanced Ultrasound in Distinguishing Intrahepatic Cholangiocarcinoma from Hepatocellular Carcinoma.

Authors:  Jing Han; Yubo Liu; Feng Han; Qing Li; Cuiju Yan; Wei Zheng; Jianwei Wang; Zhixing Guo; Jun Wang; Anhua Li; Jianhua Zhou
Journal:  Ultrasound Med Biol       Date:  2015-09-19       Impact factor: 2.998

6.  Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound.

Authors:  Marzia Galassi; Massimo Iavarone; Sandro Rossi; Simona Bota; Sara Vavassori; Laura Rosa; Simona Leoni; Laura Venerandi; Sara Marinelli; Angelo Sangiovanni; Letizia Veronese; Mirella Fraquelli; Alessandro Granito; Rita Golfieri; Massimo Colombo; Luigi Bolondi; Fabio Piscaglia
Journal:  Liver Int       Date:  2013-02-27       Impact factor: 5.828

7.  Intrahepatic cholangiocarcinoma and hepatocellular carcinoma: differential diagnosis with contrast-enhanced ultrasound.

Authors:  Li-Da Chen; Hui-Xiong Xu; Xiao-Yan Xie; Xiao-Hua Xie; Zuo-Feng Xu; Guang-Jian Liu; Zhu Wang; Man-Xia Lin; Ming-De Lu
Journal:  Eur Radiol       Date:  2009-09-04       Impact factor: 5.315

8.  Contrast-Enhanced Ultrasound for the Characterization of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Authors:  Guang-Jian Liu; Wei Wang; Ming-De Lu; Xiao-Yan Xie; Hui-Xiong Xu; Zuo-Feng Xu; Li-Da Chen; Zhu Wang; Jin-Yu Liang; Yang Huang; Wei Li; Jin-Ya Liu
Journal:  Liver Cancer       Date:  2015-10-21       Impact factor: 11.740

Review 9.  Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management.

Authors:  Han Zhang; Tian Yang; Mengchao Wu; Feng Shen
Journal:  Cancer Lett       Date:  2015-09-25       Impact factor: 8.679

Review 10.  Imaging Diagnosis of Intrahepatic and Perihilar Cholangiocarcinoma: Recent Advances and Challenges.

Authors:  Ijin Joo; Jeong Min Lee; Jeong Hee Yoon
Journal:  Radiology       Date:  2018-06-05       Impact factor: 11.105

View more
  10 in total

1.  Using new criteria to improve the differentiation between HCC and non-HCC malignancies: clinical practice and discussion in CEUS LI-RADS 2017.

Authors:  Dan Zeng; Ming Xu; Jin-Yu Liang; Mei-Qing Cheng; Hui Huang; Jia-Ming Pan; Yang Huang; Wen-Juan Tong; Xiao-Yan Xie; Ming-De Lu; Ming Kuang; Li-Da Chen; Hang-Tong Hu; Wei Wang
Journal:  Radiol Med       Date:  2021-10-19       Impact factor: 3.469

2.  CT/MRI LI-RADS version 2018 versus CEUS LI-RADS version 2017 in the diagnosis of primary hepatic nodules in patients with high-risk hepatocellular carcinoma.

Authors:  Kun Lv; Xin Cao; Yinlei Dong; Daoying Geng; Jun Zhang
Journal:  Ann Transl Med       Date:  2021-07

3.  Utility of mean platelet volume in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.

Authors:  Xin Zhang; Wen-Juan Huang; Meng-Lin Zhang; Wen Wang; Ye Niu; Rui-Tao Wang; Zeng-Yao Liu
Journal:  BMC Gastroenterol       Date:  2022-06-06       Impact factor: 2.847

4.  Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors.

Authors:  Tyler J Fraum; Roberto Cannella; Daniel R Ludwig; Richard Tsai; Muhammad Naeem; Maverick LeBlanc; Amber Salter; Allan Tsung; Anup S Shetty; Amir A Borhani; Alessandro Furlan; Kathryn J Fowler
Journal:  Eur Radiol       Date:  2019-10-25       Impact factor: 5.315

5.  Diagnosis of Non-Hepatocellular Carcinoma Malignancies in Patients With Risks for Hepatocellular Carcinoma: CEUS LI-RADS Versus CT/MRI LI-RADS.

Authors:  Yi-Xin Hu; Jing-Xian Shen; Jing Han; Si-Yue Mao; Ru-Shuang Mao; Qing Li; Fei Li; Zhi-Xing Guo; Jian-Hua Zhou
Journal:  Front Oncol       Date:  2021-04-12       Impact factor: 6.244

6.  Classification of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Based on Radiomic Analysis.

Authors:  Xiaoliang Xu; Yingfan Mao; Yanqiu Tang; Yang Liu; Cailin Xue; Qi Yue; Qiaoyu Liu; Jincheng Wang; Yin Yin
Journal:  Comput Math Methods Med       Date:  2022-02-21       Impact factor: 2.238

7.  Conventional, functional and radiomics assessment for intrahepatic cholangiocarcinoma.

Authors:  Vincenza Granata; Roberta Fusco; Andrea Belli; Valentina Borzillo; Pierpaolo Palumbo; Federico Bruno; Roberta Grassi; Alessandro Ottaiano; Guglielmo Nasti; Vincenzo Pilone; Antonella Petrillo; Francesco Izzo
Journal:  Infect Agent Cancer       Date:  2022-03-28       Impact factor: 2.965

8.  Contrast-enhanced ultrasound Liver Imaging Reporting and Data System: Lights and shadows in hepatocellular carcinoma and cholangiocellular carcinoma diagnosis.

Authors:  Gianpaolo Vidili; Marco Arru; Giuliana Solinas; Diego Francesco Calvisi; Pierluigi Meloni; Assunta Sauchella; Davide Turilli; Claudio Fabio; Antonio Cossu; Giordano Madeddu; Sergio Babudieri; Maria Assunta Zocco; Giovanni Iannetti; Enza Di Lembo; Alessandro Palmerio Delitala; Roberto Manetti
Journal:  World J Gastroenterol       Date:  2022-07-21       Impact factor: 5.374

9.  Rapid label-free detection of cholangiocarcinoma from human serum using Raman spectroscopy.

Authors:  Peeraya Suksuratin; Rutchanee Rodpai; Vor Luvira; Pewpan M Intapan; Wanchai Maleewong; Oranat Chuchuen
Journal:  PLoS One       Date:  2022-10-13       Impact factor: 3.752

10.  Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?

Authors:  Jia-Yan Huang; Jia-Wu Li; Wen-Wu Ling; Tao Li; Yan Luo; Ji-Bin Liu; Qiang Lu
Journal:  World J Gastroenterol       Date:  2020-07-21       Impact factor: 5.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.